Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study

被引:41
作者
Estill, Janne [1 ]
Egger, Matthias [1 ]
Blaser, Nello [1 ]
Vizcaya, Luisa Salazar [1 ]
Garone, Daniela [2 ]
Wood, Robin [3 ]
Campbell, Jennifer [4 ]
Hallett, Timothy B. [5 ]
Keiser, Olivia [1 ]
机构
[1] Univ Bern, Inst Social & Prevent Med ISPM, CH-3012 Bern, Switzerland
[2] Medecins Sans Frontieres, Khayelitsha ART Programme, Geneva, Switzerland
[3] Univ Cape Town, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, ZA-7700 Rondebosch, South Africa
[4] Clinton Hlth Access Initiat, Boston, MA USA
[5] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England
基金
瑞士国家科学基金会; 美国国家卫生研究院;
关键词
antiretroviral therapy; cost-effectiveness; mathematical model; sub-Saharan Africa; viral load monitoring; CD4 CELL COUNT; SUB-SAHARAN AFRICA; DRUG-RESISTANCE; SOUTH-AFRICA; STRATEGIES; COHORT; TRANSMISSION; MUTATIONS; PROGRAM; OPTIONS;
D O I
10.1097/QAD.0b013e328360a4e5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Monitoring of HIV viral load in patients on combination antiretroviral therapy (ART) is not generally available in resource-limited settings. We examined the cost-effectiveness of qualitative point-of-care viral load tests (POC-VL) in sub-Saharan Africa. Design: Mathematical model based on longitudinal data from the Gugulethu and Khayelitsha township ART programmes in Cape Town, South Africa. Methods: Cohorts of patients on ART monitored by POC-VL, CD4 cell count or clinically were simulated. Scenario A considered the more accurate detection of treatment failure with POC-VL only, and scenario B also considered the effect on HIV transmission. Scenario C further assumed that the risk of virologic failure is halved with POC-VL due to improved adherence. We estimated the change in costs per quality-adjusted life-year gained (incremental cost-effectiveness ratios, ICERs) of POC-VL compared with CD4 and clinical monitoring. Results: POC-VL tests with detection limits less than 1000 copies/ml increased costs due to unnecessary switches to second-line ART, without improving survival. Assuming POC-VL unit costs between US$5 and US$20 and detection limits between 1000 and 10 000 copies/ml, the ICER of POC-VL was US$4010-US$9230 compared with clinical and US$5960-US$25540 compared with CD4 cell count monitoring. In Scenario B, the corresponding ICERs were US$2450-US$5830 and US$2230-US$10380. In Scenario C, the ICER ranged between US$960 and US$2500 compared with clinical monitoring and between cost-saving and US$2460 compared with CD4 monitoring. Conclusion: The cost-effectiveness of POC-VL for monitoring ART is improved by a higher detection limit, by taking the reduction in new HIV infections into account and assuming that failure of first-line ART is reduced due to targeted adherence counselling. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:1483 / 1492
页数:10
相关论文
共 41 条
[21]   Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa [J].
Keiser, Olivia ;
Chi, Benjamin H. ;
Gsponer, Thomas ;
Boulle, Andrew ;
Orrell, Catherine ;
Phiri, Sam ;
Maxwell, Nicola ;
Maskew, Mhairi ;
Prozesky, Hans ;
Fox, Matthew P. ;
Westfall, Andrew ;
Egger, Matthias .
AIDS, 2011, 25 (14) :1761-1769
[22]   Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy [J].
Keiser, Olivia ;
MacPhail, Patrick ;
Boulle, Andrew ;
Wood, Robin ;
Schechter, Mauro ;
Dabis, Francois ;
Sprinz, Eduardo ;
Egger, Matthias .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2009, 14 (10) :1220-1225
[23]   Public-health and individual approaches to antiretroviral therapy: Township South Africa and Switzerland compared [J].
Keiser, Olivia ;
Orrell, Catherine ;
Egger, Matthias ;
Wood, Robin ;
Brinkhof, Martin W. G. ;
Furrer, Hansjakob ;
van Cutsem, Gilles ;
Ledergerber, Bruno ;
Boulle, Andrew .
PLOS MEDICINE, 2008, 5 (07) :1102-1111
[24]   Laboratory Monitoring to Guide Switching Antiretroviral Therapy in Resource-Limited Settings: Clinical Benefits and Cost-Effectiveness [J].
Kimmel, April D. ;
Weinstein, Milton C. ;
Anglaret, Xavier ;
Goldie, Sue J. ;
Losina, Elena ;
Yazdanpanah, Yazdan ;
Messou, Eugene ;
Cotich, Kara L. ;
Walensky, Rochelle P. ;
Freedberg, Kenneth A. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 54 (03) :258-268
[25]   Low Levels of Antiretroviral-Resistant HIV Infection in a Routine Clinic in Cameroon that Uses the World Health Organization (WHO) Public Health Approach to Monitor Antiretroviral Treatment and Adequacy with the WHO Recommendation for Second-Line Treatment [J].
Kouanfack, Charles ;
Montavon, Celine ;
Laurent, Christian ;
Aghokeng, Avelin ;
Kenfack, Alain ;
Bourgeois, Anke ;
Koulla-Shiro, Sinata ;
Mpoudi-Ngole, Eitel ;
Peeters, Martine ;
Delaporte, Eric .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (09) :1318-1322
[26]   Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design [J].
Lawn, SD ;
Myer, L ;
Orrell, C ;
Bekker, LG ;
Wood, R .
AIDS, 2005, 19 (18) :2141-2148
[27]   Effect of adherence to HAART on viroloaic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-Treated patients [J].
Maggiolo, Franco ;
Airoldi, Monica ;
Kleinloog, Hendrik Daniel ;
Callegaro, Annapaola ;
Ravasio, Veronica ;
Arici, Claudio ;
Bombana, Enrico ;
Suter, Fredy .
HIV CLINICAL TRIALS, 2007, 8 (05) :282-292
[28]  
Medecins Sans Frontieres, 2012, UND VIR LOAD MON CAN
[29]   Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial [J].
Mermin, Jonathan ;
Ekwaru, John P. ;
Were, Willy ;
Degerman, Richard ;
Bunnell, Rebecca ;
Kaharuza, Frank ;
Downing, Robert ;
Coutinho, Alex ;
Solberg, Peter ;
Alexander, Lorraine N. ;
Tappero, Jordan ;
Campbell, James ;
Moore, David M. .
BRITISH MEDICAL JOURNAL, 2011, 343 :1134
[30]  
Ministry of Health Botswana, 2008, BOTSW NAT HIV AIDS T